Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program

References

Page 1

	Year	Citations
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis Chris H. Polman, Paul O’Connor, Eva Havrdová, New England Journal of Medicine	2006	3.3K
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis Richard A. Rudick, William H. Stuart, Peter A. Calabresi, New England Journal of Medicine	2006	1.3K
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy Gary Bloomgren, Sandra Richman, Christophe Hotermans, New England Journal of Medicine	2012	1.2K
Natalizumab Induction and Maintenance Therapy for Crohn's Disease William J. Sandborn, Jean‐Frédéric Colombel, Roberts Enns, New England Journal of Medicine	2005	919
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL Journal of Neurology Systemic SclerodermaImmunologyClinical TrialsNeurological ProgressNeurology	2009	231
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results Helmut Butzkueven, Ludwig Kappos, Fabio Pellegrini, Journal of Neurology Neurosurgery & Psychiatry	2014	171
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis Carolina Holmén, Fredrik Piehl, Jan Hillert, Multiple Sclerosis Journal	2011	104
Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study Annette Oturai, Nils Koch‐Henriksen, Thor Petersen, European Journal of Neurology	2009	88
Efficacy of natalizumab in second line therapy of relapsing–remitting multiple sclerosis: results from a multi‐center study in German speaking countries Norman Putzki, Özgür Yaldizli, M. Mäurer, European Journal of Neurology	2009	86
Swedish natalizumab (Tysabri) multiple sclerosis surveillance study Fredrik Piehl, Carolina Holmén, Jan Hillert, Neurological Sciences Systemic SclerodermaMedicineSwedish NatalizumabNeurologyMultiple Sclerosis	2010	65

Page 1